QQ客服 官方微博 反馈留言

	Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma
	Mohammed Alnaggar; Yan Xu; Jingxia Li; Junyi He; Jibing Chen; Man Li; Qingling Wu; Li Lin; Yingqing Liang; Xiaohua Wang
刊名	Journal for ImmunoTherapy of Cancer
	2019
卷号	Vol.7 No.1
关键词	Gamma delta (γδ) T cells Immunotherapy Cholangiocarcinoma Clinical trial
ISSN号	2051-1426
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4741816
专题	湖南大学
作者单位	1.Biomedical Translational Research Institute and The First Affiliated Hospital,Jinan University,Guangzhou,People’s Republic of China 2.Department of Oncology, Fuda Cancer Hospital, School of Medicine,Jinan University,Guangzhou,People’s Republic of China 3.Department of Biological Treatment Center, Fuda Cancer Hospital, School of Medicine,Jinan University,Guangzhou,People’s Republic of China
推荐引用方式 GB/T 7714	Mohammed Alnaggar,Yan Xu,Jingxia Li,et al. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma[J]. Journal for ImmunoTherapy of Cancer,2019,Vol.7 No.1.
APA	Mohammed Alnaggar.,Yan Xu.,Jingxia Li.,Junyi He.,Jibing Chen.,...&Zhinan Yin.(2019).Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.Journal for ImmunoTherapy of Cancer,Vol.7 No.1.
MLA	Mohammed Alnaggar,et al."Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma".Journal for ImmunoTherapy of Cancer Vol.7 No.1(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。